Ratings by UBS (Michael Yee)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/16/2026 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (Buy) |
|
Details | ||
| 6/15/2026 | Jade Biosciences | JBIO | New Coverage | Buy (N/A) |
16.08 (19.45) |
20.96% | Details | |
| 6/9/2026 | Revolution | RVMD | Maintain | Buy (Buy) |
|
Details | ||
| 5/28/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (Buy) |
|
Details | ||
| 5/27/2026 | Pfizer | PFE | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/26/2026 | Moderna | MRNA | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/13/2026 | AnaptysBio | ANAB | Maintain | Buy (Buy) |
|
Details | ||
| 5/4/2026 | Moderna | MRNA | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/28/2026 | Oruka Therapeutics | ORKA | Maintain | Buy (Buy) |
|
Details | ||
| 4/22/2026 | Biogen | BIIB | Upgrade | Buy (Neutral) |
183.34 (199.71) |
8.93% | Details | |
| 4/21/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 4/21/2026 | AnaptysBio | ANAB | Maintain | Buy (Buy) |
|
Details | ||
| 4/21/2026 | First Tracks Biotherapeutics | TRAX | New Coverage | Buy (N/A) |
26.93 (18.32) |
-31.97% | Details | |
| 4/20/2026 | Merck | MRK | Maintain | Buy (Buy) |
|
Details | ||
| 4/13/2026 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 4/13/2026 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 4/13/2026 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 4/6/2026 | Oruka Therapeutics | ORKA | Maintain | Buy (Buy) |
|
Details | ||
| 3/31/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 3/27/2026 | Kodiak Sciences Inc. | KOD | Maintain | Buy (Buy) |
|
Details | ||
| 3/18/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 3/17/2026 | Schrodinger | SDGR | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/17/2026 | AnaptysBio | ANAB | Maintain | Buy (N/A) |
|
Details | ||
| 3/6/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (Buy) |
|
Details | ||
| 3/3/2026 | Nuvation Bio Inc | NUVB | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/27/2026 | Revolution | RVMD | New Coverage | Buy (N/A) |
103.24 (165.81) |
60.61% | Details | |
| 2/25/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 2/24/2026 | MBX Biosciences Inc | MBX | Maintain | Buy (Buy) |
|
Details | ||
| 2/24/2026 | Arcellx Inc. | ACLX | Downgrade | Neutral (Buy) |
64.11 (115.07) |
79.49% | Details | |
| 2/18/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 2/17/2026 | Galecto | GLTO | New Coverage | Buy (N/A) |
29.12 (28.69) |
-1.48% | Details | |
| 2/10/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 2/5/2026 | Abbvie | ABBV | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/2/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 1/15/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 1/13/2026 | Abbvie | ABBV | Maintain | Neutral (Neutral) |
|
Details | ||
| 1/12/2026 | Merck | MRK | Maintain | Buy (Buy) |
|
Details | ||
| 1/12/2026 | AnaptysBio | ANAB | Maintain | Buy (Buy) |
|
Details | ||
| 1/8/2026 | Ventyx Biosciences Inc | VTYX | Downgrade | Neutral (Buy) |
10.05 (14.00) |
39.3% | Details | |
| 1/7/2026 | Abbvie | ABBV | New Coverage | Neutral (N/A) |
220.18 (230.01) |
4.46% | Details | |
| 1/7/2026 | Biogen | BIIB | New Coverage | Neutral (N/A) |
174.63 (183.34) |
4.99% | Details | |
| 1/7/2026 | Bristol-Myers Squibb Co. | BMY | New Coverage | Buy (Neutral) |
53.06 (54.70) |
3.09% | Details | |
| 1/7/2026 | Gilead Sciences | GILD | New Coverage | Buy (Neutral) |
118.30 (124.87) |
5.55% | Details | |
| 1/7/2026 | Eli Lilly | LLY | New Coverage | Buy (N/A) |
1041.51 (1102.08) |
5.82% | Details | |
| 1/7/2026 | Apogee Therapeutics Inc | APGE | New Coverage | Buy (N/A) |
77.51 (132.55) |
71.01% | Details | |
| 1/7/2026 | Allogene | ALLO | New Coverage | Buy (N/A) |
1.35 (2.10) |
55.56% | Details | |
| 1/7/2026 | Zai Lab | ZLAB | New Coverage | Buy (N/A) |
18.09 (18.48) |
2.16% | Details | |
| 1/7/2026 | Ventyx Biosciences Inc | VTYX | New Coverage | Buy (N/A) |
7.82 (10.05) |
28.52% | Details | |
| 1/7/2026 | Viridian Therapeutic | VRDN | New Coverage | Buy (N/A) |
30.20 (17.63) |
-41.62% | Details | |
| 1/7/2026 | Scholar Rock | SRRK | New Coverage | Buy (N/A) |
42.76 (49.19) |
15.04% | Details | |
| 1/7/2026 | Schrodinger | SDGR | New Coverage | Neutral (N/A) |
18.50 (15.23) |
-17.68% | Details | |
| 1/7/2026 | SAB Biotherapeutics | SABS | New Coverage | Buy (N/A) |
3.74 (3.93) |
5.08% | Details | |
| 1/7/2026 | Oruka Therapeutics | ORKA | New Coverage | Buy (N/A) |
26.88 (85.38) |
217.63% | Details | |
| 1/7/2026 | Olema Pharmaceuticals | OLMA | New Coverage | Buy (N/A) |
25.10 (10.00) |
-60.16% | Details | |
| 1/7/2026 | Nuvation Bio Inc | NUVB | New Coverage | Neutral (N/A) |
8.59 (5.76) |
-32.95% | Details | |
| 1/7/2026 | MBX Biosciences Inc | MBX | New Coverage | Buy (N/A) |
29.31 (43.91) |
49.81% | Details | |
| 1/7/2026 | Kodiak Sciences Inc. | KOD | New Coverage | Buy (N/A) |
25.00 (36.63) |
46.52% | Details | |
| 1/7/2026 | Inventiva SA | IVA | New Coverage | Buy (N/A) |
4.60 (3.51) |
-23.7% | Details | |
| 1/7/2026 | Immunocore Holdings | IMCR | New Coverage | Buy (N/A) |
32.75 (29.35) |
-10.38% | Details | |
| 1/7/2026 | Ideaya Biosciences | IDYA | New Coverage | Buy (N/A) |
34.94 (34.23) |
-2.03% | Details | |
| 1/7/2026 | Denali Therapeutics Inc. | DNLI | New Coverage | Buy (N/A) |
16.02 (24.05) |
50.12% | Details | |
| 1/7/2026 | Cogent | COGT | New Coverage | Buy (N/A) |
34.26 (35.84) |
4.61% | Details | |
| 1/7/2026 | Beam Therapeutics Inc | BEAM | New Coverage | Neutral (N/A) |
26.84 (35.53) |
32.38% | Details | |
| 1/7/2026 | AnaptysBio | ANAB | New Coverage | Buy (N/A) |
43.20 (59.99) |
38.87% | Details | |
| 1/7/2026 | Aligos Therapeutics Inc. | ALGS | New Coverage | Buy (N/A) |
8.41 (5.69) |
-32.34% | Details | |
| 1/7/2026 | Arcellx Inc. | ACLX | New Coverage | Buy (N/A) |
61.83 (64.11) |
3.69% | Details | |
| 1/7/2026 | Pfizer | PFE | New Coverage | Neutral (N/A) |
25.17 (25.08) |
-0.36% | Details | |
| 1/6/2026 | Amgen | AMGN | New Coverage | Buy (N/A) |
320.72 (344.72) |
7.48% | Details |
